Top Markets
Coin of the day
Elevation Oncology, Inc. Elevation Oncology, Inc.

Elevation Oncology, Inc.

ELEV
Rank in Stocks #29358
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company... Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. Its leading drug candidate is seribantumab, an anti-HER3 monoclonal antibody currently being evaluated in the Phase II CRESTONE trial. This study focuses on treating advanced solid tumors that harbor a neuregulin-1 fusion. The company was established in 2019 and is headquartered in New York, New York.
Share Price
$0.365
Last synced: 2025-08-01
Market Cap
$21.54M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Elevation Oncology, Inc. (ELEV)

Category

Operating Margin for Elevation Oncology, Inc. (ELEV)
Operating Margin as of 2026 TTM: 0.00%
According to Elevation Oncology, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Elevation Oncology, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
-149.01% -
US
25.72% -
AU
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.